Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Obrosova, I. G.
Right arrow Articles by Yorek, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Obrosova, I. G.
Right arrow Articles by Yorek, M. A.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 54:3435-3441, 2005
© 2005 by the American Diabetes Association, Inc.

Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase (PARP) Activation in Experimental Diabetic Neuropathy

The Relation Is Revisited

Irina G. Obrosova1,2, Viktor R. Drel1, Pal Pacher3, Olga Ilnytska1, Zhong Q. Wang1, Martin J. Stevens2, and Mark A. Yorek4

1 Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana
2 Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
3 Laboratory of Physiological Studies, National Institutes of Health/National Institute of Alcohol Abuse and Alcoholism, Bethesda, Maryland
4 Veteran Affairs Medical Center and Department of Internal Medicine, University of Iowa, Iowa City, Iowa

Poly(ADP-ribose) polymerase (PARP) activation, an important factor in the pathogenesis of diabetes complications, is considered a downstream effector of oxidative-nitrosative stress. However, some recent findings suggest that it is not necessarily the case and that PARP activation may precede and contribute to free radical and oxidant-induced injury. This study evaluated the effect of PARP inhibition on oxidative-nitrosative stress in diabetic peripheral nerve, vasa nervorum, aorta, and high glucose–exposed human Schwann cells. In vivo experiments were performed in control rats and streptozocin (STZ)-induced diabetic rats treated with and without the PARP inhibitor 3-aminobenzamide (ABA) (30 mg · kg–1 · day–1 i.p. for 2 weeks after 2 weeks of untreated diabetes). Human Schwann cells (HSC) (passages 7–10; ScienCell Research Labs) were cultured in 5.5 or 30 mmol/l glucose with and without 5 mmol/l ABA. Diabetes-induced increase in peripheral nerve nitrotyrosine immunoreactivity, epineurial vessel superoxide and nitrotyrosine immunoreactivities, and aortic superoxide production was reduced by ABA. PARP-1 (Western blot analysis) was abundantly expressed in HSC, and its expression was not affected by high glucose or ABA treatment. High-glucose–induced superoxide production and overexpression of nitrosylated and poly(ADP-ribosyl)ated protein, chemically reduced amino acid-(4)-hydroxynonenal adducts, and inducible nitric oxide synthase were decreased by ABA. We concluded that PARP activation contributes to superoxide anion radical and peroxynitrite formation in peripheral nerve, vasa nervorum, and aorta of STZ-induced diabetic rats and high- glucose–exposed HSC. The relations between oxidative-nitrosative stress and PARP activation in diabetes are bi- rather than unidirectional, and PARP activation cannot only result from but also lead to free radical and oxidant generation.


Address correspondence and reprint requests to Irina G.Obrosova, PhD, Pennington Biomedical Research Center, Louisiana State University, 6400 Perkins Rd., Baton Rouge, LA 70808. E-mail: obrosoig{at}pbrc.edu

Abbreviations: ABA, 3-aminobenzamide; HNE, hydroxynonenal; HSC, human Schwann cells; iNOS, inducible nitric oxide synthase; NAD+, nicotinamide adenine dinucleotide; PARP, poly(ADP-ribose) polymerase; PDN, peripheral diabetic neuropathy; STZ, streptozocin


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
I. G. Obrosova, O. Ilnytska, V. V. Lyzogubov, I. A. Pavlov, N. Mashtalir, J. L. Nadler, and V. R. Drel
High-Fat Diet Induced Neuropathy of Pre-Diabetes and Obesity: Effects of "Healthy" Diet and Aldose Reductase Inhibition
Diabetes, October 1, 2007; 56(10): 2598 - 2608.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
P. Pacher, J. S. Beckman, and L. Liaudet
Nitric Oxide and Peroxynitrite in Health and Disease
Physiol Rev, January 1, 2007; 87(1): 315 - 424.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. J. Stevens, F. Li, V. R. Drel, O. I. Abatan, H. Kim, D. Burnett, D. Larkin, and I. G. Obrosova
Nicotinamide Reverses Neurological and Neurovascular Deficits in Streptozotocin Diabetic Rats
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 458 - 464.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
C. Szabo, A. Biser, R. Benko, E. Bottinger, and K. Susztak
Poly(ADP-Ribose) Polymerase Inhibitors Ameliorate Nephropathy of Type 2 Diabetic Leprdb/db Mice
Diabetes, November 1, 2006; 55(11): 3004 - 3012.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
O. Ilnytska, V. V. Lyzogubov, M. J. Stevens, V. R. Drel, N. Mashtalir, P. Pacher, M. A. Yorek, and I. G. Obrosova
Poly(ADP-Ribose) Polymerase Inhibition Alleviates Experimental Diabetic Sensory Neuropathy
Diabetes, June 1, 2006; 55(6): 1686 - 1694.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.